Often, patients with primary immunodeficiency diseases (PID), which are marked by the absence or loss of\nfunctional antibodies, require lifelong treatment with immunoglobulin (IG) replacement therapy administered either\nintravenously (intravenous immunoglobulin [IVIG]) or subcutaneously (subcutaneous immunoglobulin [SCIG]). In patients\nwith PID, the 20% SCIG product, Ig20Gly, was shown to be efficacious and well tolerated in 2 phase 2/3 trials conducted\nin North America and Europe. This analysis evaluated patient satisfaction with Ig20Gly therapy and treatment preferences.\nMethods: This prespecified post hoc analysis showed combined data from 2 Ig20Gly pivotal trials. Treatment satisfaction.............
Loading....